Skip to content
OpenCapital
Get started
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) Q1 2026 Earnings

TCRX·Reported May 6, 2026·Before market open

TScan Therapeutics, Inc. reported Q1 2026 revenue of $982.0K (-54.8% YoY), missed analyst consensus of $2.5M by $1.5M. Diluted EPS came in at $-0.22 (+15.4% YoY).

Revenue
$982.0Kmissed by $1.5M
Consensus: $2.5M
Diluted EPS
$-0.22met estimate
Consensus: $-0.22
SEC

SEC Filings

Earnings release8-K · 0001193125-26-207549
Quarterly report10-Q · 0001193125-26-207572

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about TScan Therapeutics, Inc.'s Q1 2026 earnings report.

TScan Therapeutics, Inc. (TCRX) reported Q1 2026 earnings on May 6, 2026 before market open.

TScan Therapeutics, Inc. reported revenue of $982.0K and diluted EPS of $-0.22 for Q1 2026.

Revenue missed the consensus estimate of $2.5M by $1.5M. EPS beat the consensus estimate of $-0.22 by $0.00.

Compared to the same quarter a year prior, revenue declined 54.8% from $2.2M a year earlier and diluted EPS grew 15.4% from $-0.26.

You can read the 8-K earnings release (0001193125-26-207549) and the 10-Q periodic report (0001193125-26-207572) directly on SEC EDGAR. The filing index links above go to sec.gov.